Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

(2022) Anne M. Hause et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

(2022) Hannah G Rosenblum et al.   LANCET INFECTIOUS DISEASES

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

(2022) Gili Regev-Yochay et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

(2022) Ruth Link-Gelles et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

(2021) Johanna Chapin-Bardales et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

(2015) Tom T. Shimabukuro et al.   VACCINE